Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study

INTRODUCTION: Elevated low-density lipoprotein cholesterol (LDL-C) is a strong independent risk predictor of cardiovascular (CV) events, while interventions to reduce it remain the only evidence-based approach to reduce CV morbidity and mortality. Secondary prevention statin trials in combination wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cacciottolo, Paul J, Kostapanos, Michalis S, Hernan Sancho, Elena, Pavey, Holly, Kaloyirou, Fotini, Vamvaka, Evangelia, Helmy, Joanna, Hubsch, Annette, McEniery, Carmel M, Wilkinson, Ian B, Cheriyan, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051397/
https://www.ncbi.nlm.nih.gov/pubmed/33849844
http://dx.doi.org/10.1136/bmjopen-2020-037457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051397/
https://www.ncbi.nlm.nih.gov/pubmed/33849844
http://dx.doi.org/10.1136/bmjopen-2020-037457

Ejemplares similares